APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
← catalyst calendarSponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With Suzhou Yasheng Pharmaceutical Co., Ltd..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
100estimated
Sites
3
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-28 | actual | When the study began enrolling |
| Primary completion | 2026-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neuroblastoma
- Solid Tumor
Interventions
- Drug: APG-115
- Drug: APG-2575
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicity (Phase I)
measured Up to 21 days
Treatment-Emergent Adverse Events per NCI-CTCAE version 5.0
measured Up to 12 months
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed